Table II.
Characteristics of the cohort studies included in the present meta-analysis.
| First author year (PMID) | Location | Enrollment, n | Analysis, n | Age-matched | Gender-matched | Therapy regimen | Follow-up, weeks | Definition of renal dysfunction | Quality scorces | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Ha 2009 (19517525) | Multicentre | 290 | 290 | + | + | ADV vs. ETV | 120 | eGFR ≤50 ml/min | High | (15) |
| Gu 2010(In Chinese) | China | 585 | 479 | + | + | ADV vs. placebo | 192 | Serum creatinine >124 µmol/l | Low | (16) |
| Yu 2011 (21492508) | China | 120 | 99 | + | + | ADV+LAM vs.ETV | 96 | ≥0.5 mg/dl increase from baseline in serum creatinine | High | (17) |
| Li 2012 (22699063) | China | 101 | 101 | + | + | ADV vs. LDT | 52 | 60<eGFR<90 ml/min/1.73 m2 | Medium | (18) |
PMID, PubMed ID; ADV, adefovir dipivoxil; ETV, entecavir; eGFR, estimated glomerular filtration rate; LAM, lamivudine; LDT, telbivudine.